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INTRODUCTION
Ischemic injury to developing white matter (WM) is
of considerable clinical interest. Although the immature
central nervous system (CNS) is generally regarded to
be more resistant than the adult CNS to such insults, it
is now known that an ischemic episode between 23 and
32 weeks gestation can result in a remarkably selective
pattern of injury to the periventricular WM (1-3). In the
United States, approximately 57,000 low birthweight
infants (<1500 g) are born each year and while recent
advances in neonatal medicine mean that around 90%
of these patients survive, sadly 10% show signs of
cerebral palsy of which injury to the periventricular
WM is the most common neuropathological correlate
(4). In addition, recent estimates suggest that a
cerebrovascular event occurs in around 1 in 4000 term
births, although many more cases may go unrecognised,
further illustrating the enormous problem ischemic
injury to the developing brain poses to clinicians (5, 6).
This pattern of pathology was first noted by the great
Russian academic Virchow in 1867 (7).  A century later,
it was termed periventricular leukomalacia (PVL) by
Banker and Larrouche when describing "necrosis of the
white matter dorsal and lateral to the external angles of
the lateral ventricles" (8). PVL is now considered to
consist of two main components: a focal site of injury
characterised by necrosis of all cell types present and a
diffuse pattern of injury which appears to affect only
developing oligodendroglia leading to marked
hypomyelination (9). It was traditionally thought that
the lesion was entirely ischaemic in origin, although
numerous reports now suggest an
infective/inflammatory contribution (10,11). The
vulnerability of the developing human brain to
ischaemia has been replicated in numerous models
including mid-to-late gestation sheep, 1 day old piglets
and 5 to 7 day old rats (1,12-15). This has led to an
intensive investigation of the physiology behind a
pathology now acknowledged to be the leading cause of
neurological disability in infants surviving neonatal
intensive care (9,16). This review will focus on the
effects of ischemia upon developing WM, exploring the
reasons behind the sensitivity of the tissue and the
experimental data on the response of the constituent cell
types to energy deprivation.
WHY IS IMMATURE WHITE MATTER SO
VULNERABLE TO ISCHEMIA?
Cessation of blood flow to the brain results in a rapid
drop in ATP levels and consequently a loss in ionic
homeostasis. The majority of the energy consumed by
the CNS is used to power the Na+-K+ ATPase, which
maintains a high concentration of Na+ outside the cell
and a relatively high K+ concentration within the cell
(17). The concentration gradients of these two ions are
then utilised by a range of transporters to maintain the
concentration gradients of other ions, for example,
Ca2+ via the Na+-Ca2+ exchange protein. In the event
of energy deprivation, the Na+-K+ ATPase fails leading
to a rise in extracellular K + concentration, membrane
depolarisation and the opening or reversal of numerous
voltage sensitive ion channels or electrogenic
transporters respectively. But why should the brain of
the pre-term infant be deprived of energy?
VASCULAR ANATOMY AND PHYSIOLOGY OF
CEREBRAL WHITE MATTER 
The vascular biology of developing periventricular
WM appears to contribute to the predisposition of the135 2006 McGill Journal of Medicine
area to ischemic injury for several reasons: blood to the
periventricular WM is supplied by long and short
penetrating arteries, which branch from the middle
cerebral artery (18). Even towards the end of gestation
this vasculature is not fully developed; both the long
and short penetrating arteries are relatively few in
number with few branches (18). Thus the arterial end
zones are quite some distance from the periventricular
region, which may lead to severe ischemia should
cerebral blood flow decline.
To compound this issue, cerebral WM receives a
relatively low blood flow during development: at 1.6 to
3 mL 100g-1 min-1 just 25% of that of cortical grey
matter and less than half of the accepted value for cell
viability in the adult brain (19-22). Such a low level of
flow means that the margin by which blood flow can
fall before injury occurs is very small. A limited
vasodilatory capacity, i.e. the ability of the vasculature
to dilate or constrict depending upon changes in blood
pressure, has also been reported in premature infants
(9). One study reported a four fold increase in the risk
of PVL following identification of a "pressure-passive"
cerebral circulation further illustrating the potential for
vascular disturbances to cause serious injury in this
region (23).
OLIGODENDROGLIAL INJURY
The most common neuropathological feature of
ischemic injury to the periventricular WM is the diffuse
injury of the oligodendroglial population and
subsequent hypomyelination (24, 25). By defining the
oligodendrocyte lineage in terms of the surface antigens
expressed, the populating oligodendroglia present
during the time of peak vulnerability in human cerebral
WM have been identified as late oligodendrocyte
progenitors or oligodendrocyte precursor cells (OPCs)
(26). Many studies before and since have been able to
demonstrate a remarkable sensitivity of these actively
differentiating cells to ischaemic and oxidative stresses,
resulting in the description of maturation-dependant
characteristics which may be of crucial importance in
the pathogenesis of ischemic injury (1,27-29).
Glutamate, the most abundant neurotransmitter in the
brain, has been shown to play an important role in the
pathophysiology of OPC death. During ischaemia,
extracellular glutamate levels rise dramatically and
elevated glutamate levels have been observed in both
animal models and clinically (30,31). When this
happens both non-NMDA and NMDA receptors are
over-activated (excitotoxicity), leading to a toxic Ca2+
flux in to the cell causing OPC damage and death (28-
33). NMDA receptors have only recently been
demonstrated in both neonatal and mature
oligodendrocytes (32-35), while the expression of non-
NMDA receptors in OPCs has been known for some
time and shown to coincide with the window of
vulnerability to ischaemia (12, 28, 36). Intriguingly,
both the NMDA and non-NMDA receptors expressed in
developing WM display curious alterations in their
physiology which may contribute to the intrinsic
susceptibility of the tissue. Oligodendrocyte NMDA
receptors show only a weak voltage dependant block by
Mg2+compared with the classically described neuronal
receptor. This means that these receptors permit a
greater Ca2+ current than one might expect under the
conditions of glutamate release and membrane
depolarisation experienced during ischemia (32). In
addition, AMPA/Kainate receptors expressed in
developing oligodendroglia show reduced expression of
the GluR2 subunit and so exhibit an increased
permeability to Ca2+ (37-40). Remarkably, expression
of this subunit has even been shown to be down-
regulated following oxygen-glucose deprivation (OGD)
preconditioning in an in vitro model (28). 
While the protective effects of specific antagonists to
glutamate receptors has been confirmed in vitro, situ
and vivo (29, 32-34), the use of such drugs clinically is
currently prevented by intolerable side-effects. These
include renal toxicity due to poor water solubility in the
case of AMPA receptor antagonists and behavioural
effects due interference with synaptic function for
NMDA receptor antagonists (41-43). Recent work,
however, has revealed that these receptors may yet
prove to be viable therapeutic targets as the use of the
anti-convulsant topiramate has been shown to attenuate
selective WM damage in a rodent model of WM injury
(12). Xenon, a non-toxic anaesthetic gas that reduces
neurotransmitter release and antagonizes NMDA
receptors, has also been shown to provide significant
neuro-protection in neonatal rats (44). In addition, the
unusual subunit composition of oligodendrocyte
NMDA receptors offers the potential of a novel drug
target away from synaptic receptors (32, 33). In a recent
article on this subject it was noted that these receptors
contain the NR3 subunit, which is responsible for the
decreased Mg2+ block seen in WM NMDA receptors
(45). Currently, there are no selective agonists or
antagonists for this subunit and Lipton suggests the
development of such drugs may be of great importance
for future clinical interventions (45).   
There are many potential sources for glutamate
release during ischemia. Release from axons is one
possibility and glutamate release/depletion during
ischaemia has been reported in optic nerve and spinal
cord models (35, 46). This liberation could potentially
occur via the reversal of electrogenic Na+-dependant
glutamate transporters due to the conditions of
ischemia. For example, membrane depolarisation and aPathophysiology of Ischemic Injury 136 Vol. 9  No. 2
concurrent increase in intracellular Na+, due to an
inactivating Na+ conductance, was suggested in the
spinal cord study (46) while release following axonal
disruption is another possibility. The release of
glutamate from astrocytes, following cell death and
clasmatodendrosis (loss of cell processes), has also been
suggested (47). In a companion paper, prevention of
Na+-K+-Cl- co-transporter (NKCC) mediated astrocyte
swelling neatly prevented non-NMDA receptor
mediated rises in intracellular Ca2+ in neighbouring
oligodendroglia during OGD, indicating a potential role
for swelling mediated glutamate release (35). As well as
receptor-mediated glutamate cell death, a non-receptor
mediated affect may also operate in oligodendrocytes.
Activation of a glutamate-cystine exchanger can lead to
a reduction in cellular levels of cystine and hence
decreased synthesis of the important antioxidant
glutathione (48).  This leaves the cell vulnerable to free
radical attack, another weakness of OPCs.
That ischemia and reperfusion lead to the generation
of free radicals is well established and OPCs have been
demonstrated to be highly vulnerable to these species
compared to mature oligodendrocytes (27,48,49).
Cystine deprivation has been used to demonstrate the
sensitivity of OPCs to oxidative stress caused by
ensuing glutathione exhaustion, a treatment which has
no effect upon the viability of mature oligodendrocytes
(27,50). The exact nature of the discrepancy between
the two developmental stages still requires further
investigation but may be the result of a developmental
delay in the maturity of anti-oxidant defences such as
glutathione peroxidase and/or catalase (9). Volpe
suggests that, should these defences be overwhelmed,
hydrogen peroxide accumulates and combines with
Fe2+ accumulated during differentiation. This may then
lead, via the Fenton reaction, to the production of
hydroxyl ions and cell death (9). Although devastating
in effect this mode of injury is potentially the most
treatable via clinically safe anti-oxidants such as
vitamin E, which have the ability to rescue OPCs from
free radical mediated death (Volpe unpublished data).
Encouragingly, the phase III Stroke-Acute Ischemic
NXY treatment trial (SAINT 1) provided evidence that
NXY-059, a free-radical-trapping agent that has been
neuroprotective in animal models, may be an effective
adjunct to tissue plasminogen activator in the acute
setting (51).  
ASTROCYTES AND ISCHEMIA
Astrocytes are the most numerous cell type of the
central nervous system but there is little information on
their mechanism(s) of ischemic injury. Potential reasons
for this include their relatively high resistance to energy
deprivation and the difficulty of studying cell viability
in vivo (52,53). Thus, most studies describing astrocyte
pathophysiology have used cell culture methods to do
so and significant differences, such as an attenuated rise
in intracellular Ca2+ concentration in vitro when
compared to in situ preparations, have been noted (52-
54). Pooled studies on the response of astrocytes to
ischemia have generated several potential causes of
injury such as Ca2+ influx through L-type Ca2+
channels and Na+-Ca2+ exchange reversal, release
from internal stores and cell swelling (47,52,54-57).
Importantly, rapid astrocyte injury has been reported
after hypoxia-ischemia in the neonatal striatum
justifying investigations into astrocyte death in the
immature brain (58).
With regard to the developing brain only two of the
above studies attempted to use astrocytes in an
immature in situ environment. The first of these used
the rat optic nerve (RON) from animals aged between
post-natal day 0-2, time points prior to the migration of
oligodendroglia into the tract (52). The author was











Figure 2. Oligodendrocyte injury during ischemia. Rising levels of
glutamate over stimulate both NMDA and non-NMDA receptors
leading to a toxic influx of Ca (1 & 2). In addition, a developmental
lag in anti-oxidant defences can lead to the build up of lethal free
radicals such as the hydroxyl radical (3). 
Figure 1. Coronal section of cerebrum. The focal (black circles) and
diffuse (grey shading) components of PVL are shown in one
hemisphere and the cerebral vascular supply in the other. The long
and short penetrating arteries supply the cerebral WM, as shown.
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to ischaemia by loading the Ca2+ dye FURA-2 into the
whole optic nerve. The key findings of the paper were a
toxic Ca2+ influx mediated by T- and L-type Ca2+
channels and a protective role for the Na+-Ca2+
exchanger. However, the P0-2 RON is more immature
than the WM affected in human patients (1, 26). When
similar experiments were performed using the P8-12
RON, in which myelination is just underway (a feature
of the perinatal WM injured by ischemia), a different
mechanism of injury was found (47). In this paper
removal of extracellular Ca2+ was not protective (in
fact it increased cell death), while removal of Na2+ Cl-
or block of the NKCC with bumetanide was, suggesting
cell swelling may be an important factor in cell death.
Interestingly, analysis of volume changes during
ischaemia did not reveal any changes although in
experiments repeated in the absence of Ca2+,
significant swelling was observed. The authors
concluded that ischaemia poses an osmo-regulatory
challenge meditated by the NKCC and controlled by
Ca2+-dependant mechanisms but this does not prevent
cell death; the actual cause of cell death was not
resolved (53). Future studies utilising recent advances
in molecular biology may prove more successful in this
respect. For example, the availability of transgenic mice
generated by the laboratory of Dr. V Gallo at the
Children's National Medical Centre, Washington DC, in
which green fluorescent protein expression is under the
control of the astrocyte specific GFAP promoter, should
provide investigators with the means of assessing
astrocyte injury more thoroughly in an in situ
environment.   
Astrocytes have long been ascribed a housekeeping
function and ischaemia-induced alterations of the many
functions they perform are capable of influencing the
outcome of surrounding cells. For example, numerous
studies of energy deprivation in the perinatal brain have
reported astrocytic activation (59-62). Astrocytes may
become "activated" by inflammatory mediators in a
range of circumstances such as ischaemia and trauma
leading to a characteristic up-regulation of GFAP,
cellular hypertrophy, astrocyte proliferation and process
extension (63). The consequences of astrocytic
activation are not well understood and may be both
beneficial and detrimental. For example, free radicals
and inflammatory mediators such as TNFa may be
released with the potential to cause injury while trophic
factors such as TGFd and brain derived neurotrophic
factor are also released and, remarkably, free radical
scavenging is possible (64-69). In addition, astrocytes
may affect the outcome of neighbouring cells through
impaired K+ and glutamate uptake (70,71), further
illustrating the potential importance of astrocyte
protection.   
AXON DAMAGE DURING ISCHEMIA 
Banker and Larroche's (1962) description of PVL
noted the presence of "retraction balls and clubs", that
is, the presence of swollen axon cylinders and such
injury will undoubtedly contribute to the phenotype of
the ensuing disorder. Recently amyloid precursor
protein, a marker of the integrity of fast axonal transport
and therefore axon injury, has been detected in the
brains of infants with WM injury (59, 72-74).
Furthermore, in a developmental study on axon
conduction during acute energy deprivation, a rapid
decrease in the ability of RONs to recover electrical
activity following OGD was noted around the onset of
myelination (75). 
Although papers on the mechanisms of injury to
myelinating axons have not been forthcoming, the
response of myelinated central axons to energy
deprivation has been extensively studied, primarily
using the hypoxic rat optic nerve model (76-78). Initial
investigations revealed that a toxic Ca2+ influx was
mediated via reversal of the Na+-Ca2+ exchange
protein following a rise in intra-axonal Na+
concentration (77). This Na+ loading, caused by non-
inactivating Na+ channels, coupled with anoxia induced
membrane depolarisation drives the electrogenic Na+-
Ca2+ exchange protein into reverse operation with
catastrophic consequences for axon function (79). Some
later studies also found a protective role for specific
voltage gated Ca2+ channel antagonists (78, 80). 
Following on from these initial studies, investigators
are now beginning to look at the mechanisms behind the
injury sustained following both oxygen and glucose
withdrawal; perhaps a more clinically relevant model
given that the cessation of blood flow that occurs during
stroke will decrease the availability of both oxygen and
glucose. Using an acute brain slice preparation Tekkök
and Goldberg reported AMPA/Kainate receptor
mediated oligodendrocyte death in line with previous
studies, but also used stimulus-evoked compound action
potentials and immunohistochemistry to assess axon
integrity (81). While Ca2+ removal preserved axon
function following an insult, block of the Na+-Ca2+
exchange, in contrast to anoxia studies, provided only
partial protection. Far more effective in preserving both
compound action potential (CAP) conduction and
neurofilament immunofluorescence was
AMPA/Kainate blockade, a result which was not
attributable to the protection of neuronal somata. The
authors speculated that the underlying reasons for this
might include myelin damage, an increase in tissue
energy use or the loss of trophic support (81). Similar
protection of optic nerve axons following OGD
withdrawal has been reported in abstract form raisingPathophysiology of Ischemic Injury 138 Vol. 9  No. 2
the possibility that in the event of a more severe
metabolic insult, excitotoxicity may play an important
role in acute axonal injury (82, 83).
Simulated ischemia has also led to reports of the
"Trojan horse" of intra-axonal Ca2+ release" (84).
Ouardouz et al. demonstrated that in rat dorsal columns,
removal of bath Ca2+ did not improve post-ischemic
CAP recovery and Ca2+ imaging experiments revealed
that a rise in intracellular Ca2+ still persisted in such
experiments (85). Ryanodine or blockers of the L-type
Ca2+ channel voltage sensor (such as diltiazem) were
protective during zero Ca2+ experiments. Subsequent
immunoprecipitation and immunohistochemical studies
revealed an association between L-type Ca2+ channels
and ryanodine receptors on axons. These data led the
authors to describe a mechanism similar to the
excitation-contraction coupling seen in skeletal muscle
where ischemic depolarisation sensed by L-type
VGCCs activates ryanodine receptors on the
endoplasmic reticulum (ER) leading to the release of
damaging amounts of Ca2+. Such evidence indicates
that ischemia-induced axon injury in the developing
brain is likely to be the result of numerous pathways
operating together leading to a catastrophic loss of
function.
CONCLUSION
Although the developing brain is relatively resistant
to ischemia, severe insults can result in a
characteristically cortical-sparring pathology associated
with both mental and physical disability. Numerous
models for studying the effects of energy deprivation
upon the developing brain are now available and have
resulted in an ever growing body of literature on the
subject. An understanding of the Byzantine
pathophysiology of ischemia-induced white matter
injury is steadily leading researchers towards the
development of effective therapeutic interventions in
the near future.    
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Figure 3. Diagram illustrating mechanisms of ischemic injury to CNS
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depolarisation coupled means (3a & b). Finally, over activation of
AMPA/Kainate receptors on oligodendroglia (4) might also
contribute to the loss of functional integrity of the axon.139 2006 McGill Journal of Medicine
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